OncoHost, a technology company focused on precision medicine, announced on Monday that the Business Intelligence Group has named OncoHost as a winner in the 2026 BIG Innovation Awards in the Health category.
Additionally, OncoHost was selected as a Top 10 Innovator – Small Business, reflecting the company's leadership in developing clinically impactful technologies.
OncoHost was recognised for its PROphet platform, an AI-driven plasma-proteomics solution designed to help oncologists predict clinical benefit and therapy-related toxicity from a single pre-treatment blood test. Its first commercial offering, PROphetNSCLC, guides first-line immunotherapy decision-making in metastatic non-small cell lung cancer (NSCLC) by revealing host-response insights that extend beyond tumour-only biomarkers.
The BIG Innovation Awards are designed to honour organisations, products, and leaders transforming industries through applied innovation, intelligent platforms, and measurable real-world impact.
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
InSysBio agrees new collaborative project with BeOne Medicines
Physiomics secures new modelling contract with Numab Therapeutics
Mabwell reports first patient dosed with 7MW4911 in US trial
Atossa Therapeutics' founder and CEO named one of The Top 50 Healthcare Technology CEOs of 2025
Avacta secures FDA clearance for second pre|CISION oncology programme
Guardant Health and Merck enter multi-year oncology diagnostics collaboration
Akeso secures NMPA review acceptance for gumokimab in ankylosing spondylitis